Uses
OMNIPAQUE is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients.
Source: US FDA prescribing information
- Presentations
- 28
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Iohexol is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients, among other approved uses. MedsAcross supplies Iohexol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Radiographic Contrast Agent, X-Ray Contrast Activity
- ATC classification
- V08AB02 Iohexol · Iodinated contrast, subgroup V08AB
- US FDA first approval
- 26 December 1985
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Intravenous, Oral, Intravascular, Intra-articular, Intrathecal, Rectal
- Dosage forms
- Injection, Oral solution
- Identifiers
- UNII 4419T9MX03RxCUI 5956CAS 66108-95-0DrugBank DB01362Q410683
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.
Source: US FDA prescribing information
Dosing overview
For each imaging procedure, specific dosage forms, concentrations, and presentations are recommended. Individualize the concentration and volume according to the specific dosing tables and accounting for factors such as age, body weight, and condition of the patient, and the equipment and imaging technique used. See full prescribing information for complete dosing and administration information.
Source: US FDA prescribing information
Contraindications
OMNIPAQUE for hysterosalpingography is contraindicated during pregnancy or suspected pregnancy, menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract including the external genitalia, and when reproductive tract neoplasia is known or suspected because of the risk of peritoneal spread of neoplasm.
Source: US FDA prescribing information
Warnings and precautions
Boxed warning (risks associated with intrathecal administration of omnipaque injection 140): mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure. Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Always have emergency equipment and trained personnel available. Acute Kidney Injury: Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk. Cardiovascular Adverse Reactions: Hemodynamic disturbances including shock and cardiac arrest may occur during or after administration. Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity.
Source: US FDA prescribing information
Side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Intrathecal Administration of OMNIPAQUE Injection 140 mg Iodine/mL and 350 mg Iodine/mL Risks Associated with Parenteral Administration of OMNIPAQUE Oral Solution Hypersensitivity Reactions Acute Kidney Injury Cardiovascular Adverse Reactions Thromboembolic Events Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age Severe Cutaneous Adverse Reactions Most common adverse reactions (incidence ≥ 1%) in adult patients Intrathecal: Headaches, pain including backache, neckache, stiffness and neuralgia, nausea, vomiting, dizziness Intra-arterial or intravenous: Pain, vision abnormalities (including blurred vision and photomas), headache, taste perversion, arrhythmias including premature ventricular contractions (PVCs) and premature atrial contractions (PACs)…
Source: US FDA prescribing information
Interactions
Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis. Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function. Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2, in patients with a history of hepatic impairment, alcoholism or heart failure, or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable. Radioactive Iodine OMNIPAQUE may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post OMNIPAQUE.
Source: US FDA prescribing information
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). May be stored in a contrast media warmer for up to one month, not to exceed 37°C (98.6°F). OMNIPAQUE Oral Solution: Store between 0°C and 30°C (32°F to 86°F). Do not freeze. Discard any product that is inadvertently frozen, as freezing may compromise the closure integrity of the immediate container. Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
28 presentations of Iohexol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Omnipaque 12000 mg/50 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 9000 mg/30 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Iohexol 15000 mg/50 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Iohexol 17500 mg/50 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Iohexol 22500 mg/75 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Iohexol 26250 mg/75 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Iohexol 30000 mg/100 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Iohexol 35000 mg/100 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectalGeneric name | — | US FDA | Available on request |
| Omnipaque 12 mg/mL oral solutionOral | GE Healthcare | US FDA | Available on request |
| Omnipaque 15000 mg/50 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 150000 mg/500 mL injectionIntravenous | GE Healthcare | US FDA | Available on request |
| Omnipaque 17500 mg/50 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 175000 mg/500 mL injectionIntravenous | GE Healthcare | US FDA | Available on request |
| Omnipaque 1800 mg/10 mL injectionIntrathecal, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 2400 mg/10 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 24000 mg/100 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 26250 mg/75 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 3000 mg/10 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 30000 mg/100 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 35000 mg/100 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 37500 mg/125 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 43750 mg/125 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 45000 mg/150 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 4800 mg/20 mL injectionIntra-articular, intrathecal, intravascular, intravenous, oral, rectal | GE Healthcare | US FDA | Available on request |
| Omnipaque 52500 mg/150 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 7000 mg/50 mL injectionIntravascular, intravenous | GE Healthcare | US FDA | Available on request |
| Omnipaque 70000 mg/200 mL injectionIntra-articular, intravascular, intravenous, oral | GE Healthcare | US FDA | Available on request |
| Omnipaque 9 mg/mL oral solutionOral | GE Healthcare | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 26 December 1985 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Questions and answers
Is Iohexol available for export from India?
Yes, on request. MedsAcross lists 28 presentations of Iohexol and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Iohexol have?
The catalogue lists 1 brand names for Iohexol, including Omnipaque.
Is Iohexol approved by the US FDA?
Yes. The US FDA first approved Iohexol on 26 December 1985, according to Drugs@FDA.
Does Iohexol need cold chain shipping?
No listed presentation of Iohexol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Iohexol in?
Iohexol is classified under ATC code V08AB02 (Iohexol).
References
- OMNIPAQUE prescribing information (GE Healthcare). U.S. National Library of Medicine, DailyMed. Retrieved 7 April 2026
Request Iohexol for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.